TREATMENT PATTERNS AMONG INDIVIDUALS WITH HEREDITARY ANGIOEDEMA IN THE UNITED STATES

• Published in: Annals of allergy, asthma, & immunology Vol. 131; no. 5; pp. S39 - S40
• Main Authors: Tachdjian, R., Chang, R., DerSarkissian, M., Cribbs, K., Lahue, B., Czado, S., Desai, V.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.11.2023
• ISSN: 1081-1206; 1534-4436
• DOI: 10.1016/j.anai.2023.08.126

Given the rapidly evolving therapeutic landscape of hereditary angioedema (HAE), this study sought to explore current treatment patterns among people living with this disease in the United States. We analyzed IQVIA PharMetrics® Plus Database records (April 2017 to March 2022). Eligible patients had either ≥1 claim for exclusively HAE-indicated therapies or ≥2 claims with HAE-associated codes and ≥1 claim for other HAE medications, were ≥12 years at index (i.e., first HAE prophylactic treatment claim), had ≥6 months of continuous enrollment (CE) before index, and ≥3 months of CE following index. Analysis focused on patients who received both prophylactic and on-demand HAE treatments. The analytic cohort consisted of 672 individuals with a mean age of 42 ± 15 years; 73% were female. During a median 20-month follow-up, 39% of patients had claims for any on-demand treatment (unadjusted for follow-up time). Icatibant was the most commonly filled on-demand treatment (71%), followed by plasma-derived C1-inhibitor (pdC1-INH) (27%). The dispensation rate for on-demand treatment was 3.9 per patient per year (95% confidence interval [CI] 3.7, 4.1). Tranexamic acid (52%), lanadelumab (23%), and C1-INH [subcutaneous] (15%) were the most frequently filled prophylactic treatments. This real-world analysis revealed that patients using prophylactic HAE treatment still require on-demand therapy, indicating persistent unmet treatment needs despite the availability of modern therapeutics. These findings reinforce the importance of readily accessible on-demand therapy aligned to clinical treatment guidelines and highlight the potential for improved disease management.